Original Article
Author Details :
Volume : 7, Issue : 4, Year : 2020
Article Page : 652-656
https://doi.org/10.18231/j.ijca.2020.117
Abstract
Background and Aims: Subarachnoid block (SAB) using Bupivacaine lacks postoperative analgesia. Aim of present study was to assess safety and efficacy of 50 m and 100m intrathecal Neostigmine for postoperative analgesia.
Materials and Methods: Ninety patients of age 18 to 65 were allocated randomly to three groups of 30 each and studied prospectively by double blind controlled trial. Patient posted for lower limb and lower abdominal surgeries were given SAB using 3 ml Bupivacaine 0.5% in group A, 2.9 ml Bupivacaine + 50 m Neostigmine in B and 2.8 ml Bupivacaine and 100m Neostigmine in C.
Patients were monitored for onset, regression of sensory and motor block, blood pressure and heart rate.
Postoperatively patients were assessed for pain score using visual analogue scale (VAS) and duration of analgesia by rescue analgesia requirement.
Results: 90 patients enrolled were analysed. VAS pain score was more in group A compared to B which had higher than group C. Analgesia was prolonged in group C than in B which had better analgesia than group A. Incidence of nausea, vomiting and bradycardia was higher with 100m Neostigmine than 50 m.
Conclusion: Intrathecal Neostigmine 50 m dose as an adjuvant to Bupivacaine is associated with good postoperative analgesia and hemodynamic stability while 100 m dose was associated with more prolonged analgesia and higher incidence of adverse effects.
Keywords: Intrathecal Neostigmine, Postoperative analgesia, VAS pain score 1.
How to cite : Ruparel D H , Dhumane P , Rathi A , Comparison of two different doses of intrathecal Neostigmine as an adjuvant to Bupivacaine for postoperative analgesia. Indian J Clin Anaesth 2020;7(4):652-656
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.